{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T23:17:16Z","timestamp":1772925436950,"version":"3.50.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,5,14]],"date-time":"2018-05-14T00:00:00Z","timestamp":1526256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,1]]},"DOI":"10.1093\/mmy\/myy025","type":"journal-article","created":{"date-parts":[[2018,4,7]],"date-time":"2018-04-07T11:08:55Z","timestamp":1523099335000},"page":"265-269","source":"Crossref","is-referenced-by-count":9,"title":["Burden of acute kidney injury in HIV patients under deoxycholate amphotericin B therapy for cryptococcal meningitis and cost-minimization analysis of amphotericin B lipid complex"],"prefix":"10.1093","volume":"57","author":[{"given":"Felipe Francisco","family":"Tuon","sequence":"first","affiliation":[{"name":"Department of Medicine, School of Medicine, Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1, Curitiba, PR, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaiany Lino","family":"Florencio","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Hospital de Cl\u00ednicas da Universidade Federal do Paran\u00e1, Curitiba, PR, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime L","family":"Rocha","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1, Curitiba, PR, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,5,14]]},"reference":[{"key":"key\n\t\t\t\t2019030416260215800_bib1","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/cid\/cit794","article-title":"Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes","volume":"58","author":"Jarvis","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019030416260215800_bib2","first-page":"CD010481","article-title":"Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function","volume":"11","author":"Botero Aguirre","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t2019030416260215800_bib3","first-page":"CD000969","article-title":"Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia","volume":"9","author":"Johansen","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t2019030416260215800_bib4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.riam.2017.03.003","article-title":"Long-term cost-effectiveness of lipid formulations of amphotericin B in the empirical therapy of invasive mycosis in a developing country","volume":"34","author":"Tuon","year":"2017","journal-title":"Rev Iberoam Micol"},{"key":"key\n\t\t\t\t2019030416260215800_bib5","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph\/ABLC Collaborative Study Group","volume":"31","author":"Wingard","year":"2000","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019030416260215800_bib6","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1086\/380844","article-title":"Amphotericin B: is a lipid-formulation gold standard feasible","volume":"38","author":"Spellberg","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019030416260215800_bib7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2165\/00002018-199513040-00001","article-title":"Lipid formulations of amphotericin B. Less toxicity but at what economic cost","volume":"13","author":"Tollemar","year":"1995","journal-title":"Drug Saf"},{"key":"key\n\t\t\t\t2019030416260215800_bib8","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019030416260215800_bib9","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc5713","article-title":"Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury","volume":"11","author":"Mehta","year":"2007","journal-title":"Crit Care"},{"key":"key\n\t\t\t\t2019030416260215800_bib10","doi-asserted-by":"crossref","first-page":"S414","DOI":"10.1086\/429335","article-title":"Study of renal safety in amphotericin B lipid complex-treated patients","volume":"40","author":"Alexander","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019030416260215800_bib11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/clinids\/22.2.315","article-title":"Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS","volume":"22","author":"Sharkey","year":"1996","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019030416260215800_bib12","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/hdi.12216","article-title":"Survival after acute kidney injury requiring dialysis: long-term follow up","volume":"18","author":"Duran","year":"2014","journal-title":"Hemodial Int"},{"key":"key\n\t\t\t\t2019030416260215800_bib13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40697-015-0068-3","article-title":"Comorbidity burden at dialysis initiation and mortality: A cohort study","volume":"2","author":"Gomez","year":"2015","journal-title":"Can J Kidney Health Dis"},{"key":"key\n\t\t\t\t2019030416260215800_bib14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1524-4733.2001.43040.x","article-title":"Health economic guidelines: similarities, differences and some implications","volume":"4","author":"Hjelmgren","year":"2001","journal-title":"Value Health"},{"key":"key\n\t\t\t\t2019030416260215800_bib15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1471-2334-12-83","article-title":"Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain","volume":"12","author":"Grau","year":"2012","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t2019030416260215800_bib16","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1200\/JCO.2000.18.12.2476","article-title":"Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients","volume":"18","author":"Cagnoni","year":"2000","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019030416260215800_bib17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2165\/00019053-200422050-00004","article-title":"Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections","volume":"22","author":"Kuti","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"key\n\t\t\t\t2019030416260215800_bib18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/jac\/dkn459","article-title":"Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia","volume":"63","author":"Al-Badriyeh","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019030416260215800_bib19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00044011-200727040-00002","article-title":"Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia","volume":"27","author":"Collins","year":"2007","journal-title":"Clin Drug Investig"},{"key":"key\n\t\t\t\t2019030416260215800_bib20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S1130-6343(05)73629-1","article-title":"[Economic evaluation of voriconazole versus amphotericin B in the treatment of invasive aspergilosis]","volume":"29","author":"Grau Cerrato","year":"2005","journal-title":"Farm Hosp"},{"key":"key\n\t\t\t\t2019030416260215800_bib21","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/myc.12036","article-title":"Pharmacoeconomic assessment of therapy for invasive aspergillosis","volume":"56","author":"Luong","year":"2013","journal-title":"Mycoses"},{"key":"key\n\t\t\t\t2019030416260215800_bib22","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/myc.12071","article-title":"Economic evaluation of micafungin vs. liposomal amphotericin B (LAmB) for the treatment of candidaemia and invasive candidiasis (IC)","volume":"56","author":"Neoh","year":"2013","journal-title":"Mycoses"},{"key":"key\n\t\t\t\t2019030416260215800_bib23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/2050-6511-15-52","article-title":"Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain","volume":"15","author":"Ostermann","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"key":"key\n\t\t\t\t2019030416260215800_bib24","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1186\/1471-2334-13-560","article-title":"Pharmacoeconomic evaluation of voriconazole vs. liposomal amphotericin B in empiric treatment of invasive fungal infections in Turkey","volume":"13","author":"Turner","year":"2013","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t2019030416260215800_bib25","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2146\/ajhp050521","article-title":"Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever","volume":"64","author":"Wingard","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"key\n\t\t\t\t2019030416260215800_bib26","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/myc.12283","article-title":"Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study","volume":"58","author":"Falci","year":"2015","journal-title":"Mycoses"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/mmy\/article-pdf\/57\/3\/265\/28010325\/myy025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T21:27:09Z","timestamp":1551734829000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/57\/3\/265\/4995747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,14]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,5,14]]},"published-print":{"date-parts":[[2019,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myy025","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"value":"1369-3786","type":"print"},{"value":"1460-2709","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4]]},"published":{"date-parts":[[2018,5,14]]}}}